Brainsway (NASDAQ:BWAY) Downgraded by Zacks Research to “Hold”

Zacks Research lowered shares of Brainsway (NASDAQ:BWAY) from a strong-buy rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Brainsway in a research note on Friday, July 17th. Weiss Ratings reissued a “buy (b-)” rating on shares of Brainsway in a report on Tuesday, July 21st. New Street Research reissued a “buy” rating on shares of Brainsway in a report on Friday, July 24th. Finally, BTIG Research lifted their target price on shares of Brainsway from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.33.

Brainsway Price Performance

NASDAQ:BWAY opened at $16.60 on Tuesday. The company has a market cap of $666.16 million, a P/E ratio of 47.43 and a beta of 1.24. The firm’s fifty day moving average price is $15.08 and its two-hundred day moving average price is $14.33. Brainsway has a one year low of $6.25 and a one year high of $17.40.

Brainsway (NASDAQ:BWAY) last posted its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. The company had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.54 million. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. As a group, equities research analysts expect that Brainsway will post 0.33 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BWAY. Masters Capital Management LLC grew its position in Brainsway by 65.0% in the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after purchasing an additional 650,000 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after acquiring an additional 241,560 shares during the period. Y.D. More Investments Ltd lifted its position in shares of Brainsway by 136.6% during the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after buying an additional 157,042 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Brainsway by 262.5% during the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after buying an additional 163,925 shares in the last quarter. Finally, ARK Investment Management LLC purchased a new stake in shares of Brainsway during the fourth quarter worth $2,422,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Trending Headlines about Brainsway

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Quarterly earnings beat expectations: BrainsWay reported second-quarter EPS of $0.14, versus the $0.10 analyst consensus, while revenue of $17.11 million exceeded estimates of $16.54 million. Revenue increased 35% year over year to a record level, and the company posted a 15.68% net margin. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Revenue guidance was raised or reaffirmed above consensus: Management guided for fiscal 2026 revenue of $68 million to $70 million, compared with the $67.8 million consensus estimate. The outlook supports expectations for continued demand for BrainsWay’s noninvasive deep transcranial magnetic stimulation systems. BrainsWay Earnings Report and Conference Call
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $18 to $20 and maintained a Buy rating, implying additional upside based on the referenced $16.60 share price. BrainsWay Price Target Raised by BTIG
• Neutral Sentiment: Momentum is strong, but valuation warrants attention: BWAY is trading near its one-year high and above its 50-day and 200-day moving averages. However, its price-to-earnings ratio of 47.43 leaves the stock sensitive to any slowdown in growth or future earnings disappointments. Brainsway Sets New 1-Year High Following Strong Earnings
• Neutral Sentiment: Reported short interest was listed as zero shares, so the data does not indicate meaningful short-covering pressure or a significant short-interest overhang.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.